Table 3.
Concomitant treatments in patients with PSS.
| Overall PSS (n = 2190) |
BoNT-A (n = 559) |
Non-BoNT-A (n = 1631) |
|
|---|---|---|---|
| Non-pharmacological, n (%) & | 1122 (51.2) | 285 (51.0) | 837 (51.3) |
| Rehabilitation and physiotherapy | 1072 (95.5) | 261 (91.6) | 811 (96.9) |
| Others | 69 (6.1) | 23 (8.1) | 46 (5.5) |
| Casts | 51 (4.5) | 17 (6.0) | 34 (4.1) |
| Cryotherapy | 43 (3.8) | 20 (7.0) | 23 (2.7) |
| Pharmacological, n (%) & | 798 (36.4) | 252 (45.1) | 546 (33.5) |
| Diazepam | 363 (45.4) | 119 (47.2) | 244 (44.7) |
| Pregabalin | 271(34.0) | 77 (30.6) | 194 (35.5) |
| Gabapentin | 255 (32.0) | 88 (34.9) | 167 (30.6) |
| Baclofen (oral or intrathecal) | 150 (18.8) | 54 (21.4) | 96 (17.6) |
| Others | 72 (9.0) | 26 (10.3) | 46 (8.4) |
In some cases, patients had more than one treatment so the sum of patients might add up to more than 100% in each section. The denominator of percentages of the subcategories in bold is based on the N of the overall sample—patients treated with BoNT-A and patients not treated with BoNT-A. The denominator of percentages in indented rows is based on the N of the parent categories. & The data reflect the number (n) and percentage (%) of patients with available information for this variable.